• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Extreme body mass index and survival in newly diagnosed multiple myeloma patients.极端体重指数与新诊断的多发性骨髓瘤患者的生存率
Blood Cancer J. 2023 Jan 12;13(1):13. doi: 10.1038/s41408-022-00782-7.
2
Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.环磷酰胺、硼替佐米与地塞米松适应性强化治疗对比未强化治疗用于新诊断的多发性骨髓瘤患者（骨髓瘤XI）：一项多中心、开放标签、随机、3期试验
Lancet Haematol. 2019 Dec;6(12):e616-e629. doi: 10.1016/S2352-3026(19)30167-X. Epub 2019 Oct 14.
3
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.达雷妥尤单抗联合硼替佐米、美法仑和泼尼松治疗新诊断多发性骨髓瘤（ALCYONE）的总生存：一项随机、开放标签、3 期临床试验。
Lancet. 2020 Jan 11;395(10218):132-141. doi: 10.1016/S0140-6736(19)32956-3. Epub 2019 Dec 10.
4
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.自体造血干细胞移植对比硼替佐米-美法仑-泼尼松（联合或不联合硼替佐米-来那度胺-地塞米松巩固治疗）以及来那度胺维持治疗用于新诊断的多发性骨髓瘤（EMN02/HO95）：一项多中心、随机、开放标签的3期研究
Lancet Haematol. 2020 Jun;7(6):e456-e468. doi: 10.1016/S2352-3026(20)30099-5. Epub 2020 Apr 30.
5
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.卡非佐米或硼替佐米联合来那度胺和地塞米松治疗无即刻自体干细胞移植意向的新诊断多发性骨髓瘤患者（ENDURANCE）：一项多中心、开放标签、3 期、随机、对照临床试验。
Lancet Oncol. 2020 Oct;21(10):1317-1330. doi: 10.1016/S1470-2045(20)30452-6. Epub 2020 Aug 28.
6
Hematology: Bortezomib in newly diagnosed multiple myeloma.血液学：硼替佐米用于新诊断的多发性骨髓瘤
Nat Rev Clin Oncol. 2009 May;6(5):255-6. doi: 10.1038/nrclinonc.2009.47.
7
Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.硼替佐米联合来那度胺和地塞米松与单纯来那度胺和地塞米松治疗新诊断的无立即自体干细胞移植意向的骨髓瘤患者（SWOG S0777）：一项随机、开放标签的3期试验
Lancet. 2017 Feb 4;389(10068):519-527. doi: 10.1016/S0140-6736(16)31594-X. Epub 2016 Dec 23.
8
Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.硼替佐米和长春新碱相关的多发性骨髓瘤患者周围神经病的发病机制：HOVON-65/GMMG-HD4 试验前瞻性数据分析。
Lancet Oncol. 2010 Nov;11(11):1057-65. doi: 10.1016/S1470-2045(10)70206-0. Epub 2010 Sep 21.
9
Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data.硼替佐米为基础的治疗方案在不适合自体造血干细胞移植的初诊多发性骨髓瘤患者中的应用：捷克注册研究数据。
Eur J Haematol. 2021 Oct;107(4):466-474. doi: 10.1111/ejh.13683. Epub 2021 Jul 28.
10
Whole-body MRI quantitative biomarkers are associated significantly with treatment response in patients with newly diagnosed symptomatic multiple myeloma following bortezomib induction.全身 MRI 定量生物标志物与硼替佐米诱导后新诊断为有症状多发性骨髓瘤患者的治疗反应显著相关。
Eur Radiol. 2017 Dec;27(12):5325-5336. doi: 10.1007/s00330-017-4907-8. Epub 2017 Jun 27.

引用本文的文献

1
AI-based body composition analysis of CT data has the potential to predict disease course in patients with multiple myeloma.基于人工智能的CT数据身体成分分析有潜力预测多发性骨髓瘤患者的疾病进程。
Sci Rep. 2025 Jul 21;15(1):26455. doi: 10.1038/s41598-025-11560-3.
2
Impact of obesity on cancer therapy outcomes: a multicenter cohort study of 30-day mortality and morbidity.肥胖对癌症治疗结局的影响：一项关于30天死亡率和发病率的多中心队列研究
Anticancer Drugs. 2025 Jul 1;36(6):489-494. doi: 10.1097/CAD.0000000000001703. Epub 2025 Apr 10.
3
Impact of body mass index on outcomes of multiple myeloma patients undergoing upfront autologous stem cell transplant.体重指数对接受一线自体干细胞移植的多发性骨髓瘤患者预后的影响。
Br J Haematol. 2025 Feb;206(2):763-765. doi: 10.1111/bjh.19937. Epub 2024 Nov 28.
4
The role of nutrition and gut microbiome in the progression of multiple myeloma and its precursor disease.营养和肠道微生物群在多发性骨髓瘤及其前驱疾病进展中的作用。
Front Oncol. 2024 Oct 14;14:1461128. doi: 10.3389/fonc.2024.1461128. eCollection 2024.
5
Adipocytes and metabolism: Contributions to multiple myeloma.脂肪细胞与代谢：对多发性骨髓瘤的影响
J Bone Oncol. 2024 May 22;46:100609. doi: 10.1016/j.jbo.2024.100609. eCollection 2024 Jun.
6
Association between CTX-1 and Fibulin-1 Serum Levels with Pathogenesis of Multiple Myeloma Cancer.CTX-1 和 Fibulin-1 血清水平与多发性骨髓瘤发病机制的相关性。
Asian Pac J Cancer Prev. 2024 May 1;25(5):1599-1605. doi: 10.31557/APJCP.2024.25.5.1599.
7
Design and Rationale of Prolonged Nightly Fasting for Multiple Myeloma Prevention (PROFAST): Protocol for a Randomized Controlled Pilot Trial.延长夜间禁食预防多发性骨髓瘤（PROFAST）的设计与原理：一项随机对照试验的方案
JMIR Res Protoc. 2024 Mar 11;13:e51368. doi: 10.2196/51368.
8
Non-Toxicological Role of Aryl Hydrocarbon Receptor in Obesity-Associated Multiple Myeloma Cell Growth and Survival.芳烃受体在肥胖相关多发性骨髓瘤细胞生长和存活中的非毒理学作用
Cancers (Basel). 2023 Nov 1;15(21):5255. doi: 10.3390/cancers15215255.
9
Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups.不同种族群体中多发性骨髓瘤患者糖尿病的患病率及其对生存的影响。
Blood Adv. 2024 Jan 9;8(1):236-247. doi: 10.1182/bloodadvances.2023010815.

本文引用的文献

1
A comprehensive review of the impact of obesity on plasma cell disorders.肥胖对浆细胞疾病影响的综合综述。
Leukemia. 2022 Feb;36(2):301-314. doi: 10.1038/s41375-021-01443-7. Epub 2021 Oct 15.
2
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial.简化的虚弱评分可预测 FIRST（MM-020）试验中新诊断的不适合移植的多发性骨髓瘤患者的结局。
Leukemia. 2020 Jan;34(1):224-233. doi: 10.1038/s41375-019-0539-0. Epub 2019 Aug 19.
3
Body mass index throughout adulthood, physical activity, and risk of multiple myeloma: a prospective analysis in three large cohorts.成年期体重指数、身体活动与多发性骨髓瘤风险：三项大型队列前瞻性分析。
Br J Cancer. 2018 Apr;118(7):1013-1019. doi: 10.1038/s41416-018-0010-4. Epub 2018 Mar 12.
4
Explaining the Obesity Paradox: The Association between Body Composition and Colorectal Cancer Survival (C-SCANS Study).解读肥胖悖论：身体成分与结直肠癌生存之间的关联（C-SCANS研究）
Cancer Epidemiol Biomarkers Prev. 2017 Jul;26(7):1008-1015. doi: 10.1158/1055-9965.EPI-17-0200. Epub 2017 May 15.
5
The Evolution of Prognostic Factors in Multiple Myeloma.多发性骨髓瘤预后因素的演变
Adv Hematol. 2017;2017:4812637. doi: 10.1155/2017/4812637. Epub 2017 Feb 21.
6
Next Steps in Understanding the Obesity Paradox in Cancer.理解癌症中的肥胖悖论的后续步骤。
Cancer Epidemiol Biomarkers Prev. 2017 Jan;26(1):12. doi: 10.1158/1055-9965.EPI-16-0764.
7
Body Fatness and Cancer--Viewpoint of the IARC Working Group.身体肥胖与癌症——国际癌症研究机构工作组的观点
N Engl J Med. 2016 Aug 25;375(8):794-8. doi: 10.1056/NEJMsr1606602.
8
Signaling Interplay between Bone Marrow Adipose Tissue and Multiple Myeloma cells.骨髓脂肪组织与多发性骨髓瘤细胞之间的信号相互作用。
Front Endocrinol (Lausanne). 2016 Jun 17;7:67. doi: 10.3389/fendo.2016.00067. eCollection 2016.
9
Adipocytes contribute to the growth and progression of multiple myeloma: Unraveling obesity related differences in adipocyte signaling.脂肪细胞促进多发性骨髓瘤的生长和进展：揭示肥胖相关的脂肪细胞信号差异。
Cancer Lett. 2016 Sep 28;380(1):114-21. doi: 10.1016/j.canlet.2016.06.010. Epub 2016 Jun 16.
10
Multiple Myeloma Mortality in Relation to Obesity Among African Americans.非裔美国人中肥胖与多发性骨髓瘤死亡率的关系
J Natl Cancer Inst. 2016 May 4;108(10). doi: 10.1093/jnci/djw120. Print 2016 Oct.

Extreme body mass index and survival in newly diagnosed multiple myeloma patients.

作者信息

Shah Urvi A, Whiting Karissa, Devlin Sean, Ershler Rachel, Kanapuru Bindu, Lee David J, Tahri Sabrin, Gwise Thomas, Rustad Even H, Mailankody Sham, Lesokhin Alexander M, Kazandjian Dickran, Maura Francesco, Auclair Daniel, Birmann Brenda M, Usmani Saad Z, Gormley Nicole, Marinac Catherine R, Landgren Ola

机构信息

Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.

Department of Medicine, Weill Cornell Medical College, 400 East 67th Street, New York, NY, 10065, USA.

出版信息

Blood Cancer J. 2023 Jan 12;13(1):13. doi: 10.1038/s41408-022-00782-7.

DOI:10.1038/s41408-022-00782-7
PMID:36631444
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9834289/
Abstract
摘要